APIs pour la recherche et les impuretés

Ibuprofen EP impurity H is an impurity of ibuprofen. It is a white crystalline powder with a melting point of 182-184°C and a molecular weight of 253.3. Ibuprofen EP impurity H can be synthesized in high purity by reacting 4-bromobenzenesulfonyl chloride with 2-hydroxybenzoic acid in the presence of triethylamine. This impurity has been used as a standard for drug product analysis, pharmacopoeia standards, drug development, and metabolism studies. Ibuprofen EP impurity H can be identified by HPLC using a retention time of 17.2 minutes and an UV absorption maximum at 254 nm.

Please enquire for more information about 2-[4-(Dimethylamino)-1-(2-methylphenyl)butyl]-phenol including the price, delivery time and more detailed product information at the technical inquiry form on this page

Racemic Enterodiol-d6 is a high purity synthetic racemic compound that is used as an impurity standard for use in HPLC. The CAS number for Racemic Enterodiol-d6 is 104411-12-3. Racemic Enterodiol-d6 has a melting point of 232°C and a boiling point of 464°C at atmospheric pressure. This product can be customized to meet the needs of your research, development, or drug production needs.

Pravastatin 6-oxo Impurity is an impurity of Pravastatin, a drug used in the treatment of high cholesterol. The impurity has been identified through analytical methods and is characterized by HPLC analysis. This substance has been shown to be present in at least 0.1% of the drug product and may be present as a result of incomplete synthesis or a side-reaction during synthesis.

5-O-Desethyl amlodipine is a metabolite of amlodipine. It has been used as an analytical reference standard for the determination of amlodipine and its metabolites in human plasma and urine. 5-O-Desethyl amlodipine has been reported to be excreted in human breast milk at a concentration that is about 20% of that found in maternal plasma. The drug product is manufactured by HPLC and is classified as a high purity pharmaceutical drug, which means it is free from extraneous substances such as other drugs, proteins, or bacteria.

(Z)-Fluvoxamine-EP is a drug product that is used as an analytical standard. It is a synthetic metabolite of fluvoxamine, which is a drug used for the treatment of depression. The synthesis of (Z)-fluvoxamine-EP is based on the asymmetric synthesis of fluvoxamine and the use of chiral chromatography to purify the product. This synthetic process allows for the production of high-purity (Z)-fluvoxamine-EP with a purity greater than 99%.

L-Valine 2-hydroxyethyl ester tosylate (L-V2HT) is a drug product that is synthesized by custom synthesis. It has high purity, analytical, and natural properties. L-V2HT is metabolized through a number of metabolic transformations, including hydrolysis by esterases or glucuronidases, oxidation by cytochrome P450 enzymes, reduction by glutathione reductase, or conjugation with glucuronic acid. The active form of L-V2HT is metabolized through a number of metabolic transformations, including hydrolysis by esterases or glucuronidases, oxidation by cytochrome P450 enzymes, reduction by glutathione reductase, or conjugation with glucuronic acid. L-V2HT also specifically binds to markers expressed at high levels in Mycobacterium tuberculosis strains (e.g., ESX-1 secretion system protein) and inhibits cell

Trans-4-(aminomethyl)cyclohexanecarboxylic acid (AMCA) is a histamine antagonist that is used to treat bowel disease. It may also be useful for the treatment of other inflammatory diseases and as an anticoagulant. AMCA has been shown to be safe and effective for the prevention of postoperative bleeding in patients who are undergoing major surgery. This drug is a potent inhibitor of platelet aggregation, but does not affect the function of erythrocytes or leukocytes. AMCA inhibits platelet aggregation by blocking the binding of adenosine diphosphate (ADP) to its receptor on platelets, thus inhibiting ADP-mediated activation of phospholipase A2 and arachidonic acid release from membranes. An increase in blood levels of AMCA may lead to cardiac toxicity and bleeding events.

1-(2-Furoyl)piperazine is a potent inhibitor of tyrosinase, an enzyme involved in the production of melanin. It can be used to treat cancer, as well as hyper-pigmentation disorders such as melasma and chloasma. 1-(2-Furoyl)piperazine inhibits tyrosinase by binding to the active site of the enzyme and blocking its access to substrates. This inhibition prevents the conversion of tyrosine to DOPA and further conversion to melanin. 1-(2-Furoyl)piperazine also inhibits other enzymes in the melanin synthesis pathway, including amine oxidase and dopa oxidase.

Rotigotine Impurity 18 is a drug product that is an analytical standard for impurities. It is a synthetic impurity that is not found in natural sources. Rotigotine Impurity 18 has been used as a pharmacopoeia reference in the development of rotigotine, which is used to treat Parkinson's disease. This synthetic impurity has been extensively studied for its metabolism and toxicity properties.

Salbutamol Impurity D is a chiral, metal chelator impurity of the drug substance Salbutamol. It is a prodrug that is hydrolyzed to its active form, salbutamol sulfate, in vivo. Salbutamol Impurity D binds to chloride ions and has been shown to be an interferent for many analytical methods. The reversed-phase chromatography retention time for Salbutamol Impurity D is about 10 minutes shorter than for Salbutamol sulfate.

Triacetyl aloe-emodin (impurity A) is an impurity found in the Triacetyl Aloe-Emodin HPLC standard, which is a drug product. It is not approved for use as a drug and should be used only for research and development purposes. The impurity can be custom synthesized or purchased from a specialty chemical supplier. Impurities are not typically found in the final drug product but can occur during synthesis or purification of the API. This impurity is not present in any pharmacopoeia and has no known biological activity. The CAS number of this impurity is 25395-11-3.

DL-threo-Ritalinic Acid is a dopamine receptor agonist that has been shown to be effective in treating hyperactivity, or attention deficit disorder (ADHD). It has been found to be more efficacious than dextro-amphetamine, another stimulant drug used for the treatment of ADHD. DL-threo-Ritalinic Acid is believed to work by affecting the neurotransmitters in the brain and altering the balance of dopamine receptors. In a two-way crossover study, preschool children were given either 0.5mg/kg of DL-threo-Ritalinic Acid or placebo for three days. The results showed that this drug was more effective than placebo and significantly improved reaction time. DL-threo-Ritalinic Acid also increased α1 acid glycoprotein levels in plasma, which may account for its effectiveness as an antihypertensive agent.

Torasemide EP Impurity C is a drug product that is used as an analytical standard in the metabolism studies of torasemide. Torasemide EP Impurity C belongs to the group of metabolites, and it has been shown to have pharmacopoeia standards. Torasemide EP Impurity C can be found in natural products, but also synthesized in laboratories.

This is a white crystalline compound that has been shown to be effective against glutamic acid-sensitive L-amino acid decarboxylase. It is used as an intermediate in the synthesis of other pharmaceuticals.

Duloxetine is a drug product that belongs to the class of drugs known as selective serotonin and norepinephrine reuptake inhibitors. Duloxetine is a metabolite of duloxetine phenyl carbamate, which is an impurity standard for HPLC analysis. Duloxetine has been shown to inhibit the metabolism of serotonin and norepinephrine in the brain, leading to increased amounts of these neurotransmitters. This medication has been studied in niche populations such as those with depression and diabetic neuropathy. Duloxetine also has high purity standards, meeting the requirements of pharmacopoeia.

Regadenoson Impurity 28 is an analytical standard and research and development impurity. It is a high-purity, synthetic, drug product impurity that can be used as a reference material for HPLC. This drug impurity is also available in a custom synthesis service. Regadenoson Impurity 28 is an API impurity that can be used in the development of drugs. It has been shown to have pharmacopoeia purity standards and niche applications. Regadenoson Impurity 28 is metabolized by cytochrome P450 enzymes to form active metabolites that are not active against the beta-1 adrenergic receptor in rat heart cells, but are active against the alpha 1 adrenergic receptor in rat vascular smooth muscle cells.

N,5-Dibenzyl-5-hydroxy-indole-3-glyoxylamide is a drug product that can be used as an analytical reference standard and an impurity standard. It is used in the development of drugs, including synthetic intermediates and metabolites. N,5-Dibenzyl-5-hydroxy-indole-3-glyoxylamide is a natural metabolite. It has been shown to have antihistamine activity and to inhibit prostaglandin synthesis.